Vericel Corporation (NASDAQ: VCEL - Get Free Report) has been given a consensus rating of "Moderate Buy" by the seven analysts that are covering the firm, MarketBeat.com reports. Three investment analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 1 year price target among
Vericel Corporation (VCEL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Total Revenue Expected to be $276 Million MACI Revenue Expected to be $239.5 Million Fourth Quarter Total Revenue and MACI Revenue Growth of 23% CAMBRIDGE, Mass., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced preliminary, unaudited financial results and other business updates for the fourth quarter and year ended December 31, 2025.
CAMBRIDGE, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will present at the 44th Annual J.P. Morgan Healthcare Conference at 2:15 p.m. ET (11:15 a.m. PT) on Wednesday, January 14, 2026.
Vericel Corporation (NASDAQ: VCEL - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the seven analysts that are currently covering the stock, Marketbeat Ratings reports. Three research analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 1 year price
Frontier Capital Management Co. LLC increased its holdings in Vericel Corporation (NASDAQ: VCEL) by 74.3% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 398,960 shares of the biotechnology company's stock after buying an additional 170,006 shares during the period. Frontier Capital
Vericel Corporation (NASDAQ: VCEL - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the seven analysts that are presently covering the stock, MarketBeat reports. Three analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 1 year target price among
CAMBRIDGE, Mass., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will participate in a fireside chat at the Stephens Annual Investment Conference at 11:00 a.m. ET (10:00 a.m. CT) on Thursday, November 20, 2025.
The average of price targets set by Wall Street analysts indicates a potential upside of 39.4% in Vericel (VCEL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Vericel Corporation ( VCEL ) Q3 2025 Earnings Call November 6, 2025 8:30 AM EST Company Participants Eric Burns - Vice President of Finance & Investor Relations Dominick C. Colangelo - CEO, President & Director Joseph Mara - CFO & Treasurer Conference Call Participants Joshua Jennings - TD Cowen, Research Division Richard Newitter - Truist Securities, Inc., Research Division Ryan Zimmerman - BTIG, LLC, Research Division Caitlin Roberts - Canaccord Genuity Corp., Research Division Michael Kratky - Leerink Partners LLC, Research Division Jeffrey Cohen - Ladenburg Thalmann & Co. Inc., Research Division Presentation Operator Good day, and welcome to the Vericel Corporation Third Quarter 2025 Earnings Call.
